IMMUNEONCO-B (01541) surged more than 17%, with gains reaching 17.09% at the time of writing to trade at HK$5.55. Turnover amounted to HK$11.44 million. A recent article by PharmaCube highlighted that a paper published in the scientific journal *Science* aligns with IMMUNEONCO's development strategy for target-based therapeutics. Clinical data for IMM0306 strongly demonstrate that, with proper drug design capable of simultaneously addressing the low efficacy issue of "antigen sink" and providing synergistic activation via "dual signaling," the CD47 target retains significant clinical development value. Guoyuan International previously noted that the company's expanding R&D pipeline enhances its risk resilience. The CD47xCD20 bispecific antibody (IMM0306) has shown excellent clinical efficacy data and is expected to become a blockbuster drug in the autoimmune disease field. The company is a global innovator in CD47 fusion proteins, with a rich pipeline offering broad application prospects in oncology, autoimmune disorders, and cardiovascular diseases.